Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4831 in Heart Failure With Preserved/Mid-range Ejection Fraction (Phase 2b/3, Part A)
2020-005844-47Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mitiperstat in heart failure (HF) (3 arms), sponsored by AstraZeneca. Primary endpoint: Primary endpoint (Part A). Started Apr 2021; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2020-005844-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005844-47.